Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.97
-1.6%
$4.83
$3.42
$6.91
$285.09M1.911.46 million shs663,357 shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$4.85
-2.4%
$5.99
$3.79
$14.60
$272.83M-0.9727,173 shs739,124 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$1.19
$0.96
$0.61
$5.43
$67.35M1.25218,575 shs109,598 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$9.81
-2.8%
$11.63
$8.46
$26.50
$262.36M0.3946,373 shs47,865 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+4.34%-2.32%+12.72%-16.39%-12.33%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.55%-15.19%-17.44%-8.97%-22.83%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-4.80%+5.31%+38.78%+8.68%-76.01%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-0.98%+2.54%-4.18%-3.07%-23.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.97
-1.6%
$4.83
$3.42
$6.91
$285.09M1.911.46 million shs663,357 shs
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$4.85
-2.4%
$5.99
$3.79
$14.60
$272.83M-0.9727,173 shs739,124 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$1.19
$0.96
$0.61
$5.43
$67.35M1.25218,575 shs109,598 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$9.81
-2.8%
$11.63
$8.46
$26.50
$262.36M0.3946,373 shs47,865 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+4.34%-2.32%+12.72%-16.39%-12.33%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.55%-15.19%-17.44%-8.97%-22.83%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-4.80%+5.31%+38.78%+8.68%-76.01%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-0.98%+2.54%-4.18%-3.07%-23.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.00
BuyN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.00
Buy$20.00312.37% Upside
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.00
Buy$4.00236.13% Upside
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.80
Moderate Buy$40.00307.75% Upside

Current Analyst Ratings Breakdown

Latest PRLD, ACB, RNAC, and CADL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral$13.00 ➝ $7.00
8/18/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$4.00 ➝ $3.00
8/8/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell
7/9/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/9/2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$38.00
6/30/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy$23.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.14$0.60 per share8.26$7.78 per share0.64
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,218.88N/AN/A$1.41 per share3.44
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M9.62N/AN/A$2.39 per share0.50
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$38.91M6.56N/AN/A($0.27) per share-36.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M-$0.19N/A11.30N/A-5.66%-1.49%-1.06%11/5/2025 (Estimated)
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$55.18M-$0.69N/AN/AN/AN/A-41.00%-26.81%11/13/2025 (Estimated)
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$127.17M-$1.64N/AN/AN/AN/A-106.50%-79.07%11/5/2025 (Estimated)
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$77.42M-$52.83N/AN/AN/AN/AN/A-6.36%11/6/2025 (Estimated)

Latest PRLD, ACB, RNAC, and CADL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.17-$0.09+$0.08-$0.09N/AN/A
8/14/2025Q2 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.45-$0.41+$0.04-$0.41N/AN/A
8/7/2025Q2 2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.76$0.50+$1.26$0.50$0.77 million$0.30 million
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18-$0.19-$0.37-$0.20$96.83 million$71.98 million
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.06
2.97
1.51
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.01
7.04
7.04
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
3.68
3.68
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/A
13.33
13.33

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
86.95%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
63.90%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
60.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.45 million56.45 millionOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6054.90 million45.78 millionOptionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12056.60 million20.43 millionOptionable
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
6426.00 million10.32 millionOptionable

Recent News About These Companies

Cartesian (RNAC) Q2 Revenue Drops 99%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.97 -0.08 (-1.58%)
Closing price 04:00 PM Eastern
Extended Trading
$4.95 -0.02 (-0.40%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$4.85 -0.12 (-2.41%)
Closing price 04:00 PM Eastern
Extended Trading
$4.85 0.00 (0.00%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$1.19 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.19 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Cartesian Therapeutics stock logo

Cartesian Therapeutics NASDAQ:RNAC

$9.81 -0.28 (-2.78%)
Closing price 04:00 PM Eastern
Extended Trading
$9.82 +0.00 (+0.05%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.